D. Boral Capital lowered the firm’s price target on Biomea Fusion (BMEA) to $16 from $128 and keeps a Buy rating on the shares. The company ...

D. Boral Capital reiterated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Free Report) in a report issued on ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

HC Wainwright & Co.：重申Biomea Fusion(BMEA.US)评级，由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。 Biomea Fusion（BMEA.US）公司简介：Biomea Fusion Inc ...

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes ...

REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass ...

Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea” or "Biomea Fusion” or "the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing ...